TITLE

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

AUTHOR(S)
Feuring-Buske, M.; Kneba, M.; Unterhalt, M.; Engert, A.; Gramatzki, M.; Hiller, E.; Trümper, L.; Brugger, W.; Ostermann, H.; Atzpodien, J.; Hallek, M.; Aulitzky, E.; Hiddemann, W.; Trümper, L
PUB. DATE
September 2000
SOURCE
Annals of Hematology;Sep2000, Vol. 79 Issue 9, p493
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Purpose: The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma.Patients and Methods: The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age with relapsed advanced-stage follicular lymphomas (FL) grades I and II, according to the REAL classification, or with centroblastic/centrocytic (CB/CC lymphomas according to the Kiel classification. Four weekly doses of 375 mg/m2 rituximab were applied.Results: 38 patients from eight centers were included between January 1997 and January 1998 and were evaluable for response and toxicity on an intention to treat basis. The median age was 55 years (range 26-75 years). Thirteen patients (35%) were in first relapse, 11 patients (30%) in second, and 13 patients (35%) in third relapse. The median time between primary diagnosis and study entry was 4.6 years (range 0.9-14.7 years). Twenty-three patients tolerated the application of rituximab without adverse events; in 13 cases the infusion rate had to be reduced because of side effects; in two patients the application was stopped because of pharyngeal edema and anaphylactoid reaction. The most frequent side effects were fever (13 patients) and rigor (13 patients); 65% of the side effects were observed after the first infusion. Twenty grade-III/IV side effects were considered to be related to treatment: lymphocytopenia (3), granalocytopenia (1), thrombocytopenia (2), fever (1), hyperglycermia (1), venous thrombosis (1), syncope (1), plasmatic coagulation disorder (1), shortness of breath (2), photosensitivity (1), cardiac failure (1), chills (1), sepsis (1), tumor lysis (1), anemia (1), and pharyngeal edema (1). Eight patients were not eligible for assessment of response because of non-follicular subtypes of low-grade lymphomas (n =6) or early termination of therapy at the first infusion because of severe side effects (n =2). From the 30 evaluable cases with follicular lymphomas, five patients achieved a complete remission (CR) (17%), nine patients a partial remission (PR) (30%), and two patients a minor response (MR) (7%). The overall response rate was 47%. The median time to treatment progression (TTP) was 201 days (range 64-293 days), with five patients experiencing long-lasting remissions of 214-293 days duration. In three patients, the rituximab-induced remission exceeded the preceding progression-free interval substantially. Bulky disease (P=0.058) and/or bone-mar row involvement (P=0.046) were associated with poor response.Conclusion: This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma. Further studies are needed to determine the role of rituximab in the first-line treatment of these disorders and its combination with conventional chemotherapy.
ACCESSION #
15684621

 

Related Articles

  • The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema. Cicardi, M.; Zanichelli, A. // Current Molecular Medicine;Jun2010, Vol. 10 Issue 4, p354 

    Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent...

  • Non-Hodgkin's lymphoma update. Browett, Peter // New Zealand Doctor;5/23/2007, p21 

    The article offers information on non-Hodgkin's lymphomas. The commonly diagnosed types of non-Hodgkin's lymphoma are follicular lymphoma and diffuse large B-cell lymphoma. Signs and symptoms include lymphadenopathy, fever, sweats and weight loss. Diagnostic tests used are tissue biopsy,...

  • Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Choung, Bum-Su; Yoo, Wan-Hee // Rheumatology International;May2012, Vol. 32 Issue 5, p1353 

    Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We...

  • Multiple glioblastomas: CT and MR features. Lafitte, F.; Morel-Precetti, S.; Martin-Duverneuil, N.; Guermazi, A.; Brunet, E.; Heran, F.; Chiras, J. // European Radiology;Jan2001, Vol. 11 Issue 1, p131 

    The aim of this study was to analyze the CT and MR features of multiple glioblastomas, and to determine the best imaging modality for the initial diagnosis. The CT (four exams) and MR imaging (eight exams) of eight patients with proven multiple glioblastomas were reviewed by two...

  • Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence of RB1 copy number. Galteland, E.; Smedshammer, L. // Leukemia (08876924);Aug2002, Vol. 16 Issue 8, p1549 

    Some studies have suggested that a significant fraction of nonHodgkin's lymphomas (NHL) do not express pRB protein, possibly due to deletions of RB1. We examined RB1/centromere 17 copy number by fluorescent in situ hybridisation, and pRB expression/phosphorylation by immunohistochemistry (IHC)...

  • NHL.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1584 

    An encyclopedia entry for the acronym "NHL," which stands for non-Hodgkin's lymphoma, is presented.

  • Lymphoproliferative disorders in Oxford renal transplant recipients. Bates, W.D.; Gray, D.W.R.; Dada, M.A.; Chetty, R.; Gatter, K.C.; Davies, D.R.; Morris, P.J. // Journal of Clinical Pathology;Jun2003, Vol. 56 Issue 6, p439 

    Background: Increased cancer incidence, particularly lymphoproliferative disease, is a complication of immunosuppression in organ transplantation. Non-Hodgkin's lymphomas (NHLs) occur frequently during the first year after transplantation, more so in North America than in Europe. Methods: This...

  • Non-Hodgkin's lymphoma. I: characterisation and treatment. O'Reilly, Susan E.; Connors, Joseph M. // BMJ: British Medical Journal (International Edition);6/27/92, Vol. 304 Issue 6843, p1682 

    Evaluates the characteristics and medical intervention of non-hodgskin's lymphoma. Classification of the disease; Prognostic factors for the outcome of the disease; Staging procedures for the disease.

  • Triple-negative (CD3-/CD4-/CD8-) adult T cell leukemia/lymphoma, histologically presenting as CD30 (Ki-1)-positive anaplastic large cell lymphoma with clonal Epstein-Barr virus genome. Kumura, T; Hino, M; Yamane, T; Ohta, K; Nakao, T; Wakasa, K; Tatsumi, N // Leukemia (08876924);Jun2001, Vol. 15 Issue 6, p994 

    Focuses on the disease anaplastic large cell lymphoma (ALCL). Clinical analysis of a patient diagnosed with ALCL; Definition of ALCL; Relationship between ALCL and HTLV-1 proviral DNA infection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics